Propanc Biopharma, Inc.

PPCB

$1.01

-0.98%

N/A-$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on ...

Supply Chain of PPCB

Upstream

Foundry, packaging, memory, wafers, components, and input vendors.

Upstream

European CDMO (Contract Development & Manufacturing Organization)

Raw Material Supplier (Bovine Pancreatic Proenzymes)

University of Jaén (Spain)

University of Granada (Spain)

European CDMO (Contract Development & Manufacturing Organization)

GMP manufacturing of PRP for Phase 1b first-in-human study; end-to-end preclinical and clinical project services; operates 4,500sqm facility with biologics production expertise

Raw Material Supplier (Bovine Pancreatic Proenzymes)

Supplier of pharma-grade trypsinogen and chymotrypsinogen isolated from bovine pancreas; raw materials for PRP manufacture

University of Jaén (Spain)

Joint research partnership since 2017; multi-year anti-aging and cancer research collaboration (renewed March 2026); drug discovery and preclinical research on PRP and senescence-modulating compounds

University of Granada (Spain)

Joint research collaboration (alongside University of Jaén); five agreements over 17 years; cell rejuvenation and cancer research; PRP mechanism-of-action studies

Downstream

Customers, distributors, OEMs, and channels that absorb output.

Downstream

No commercial customers (pre-revenue stage)

Company has no approved products, no commercial revenue, and no downstream customer or distribution relationships. Phase 1b FIH study expected to enroll 30-40 advanced cancer patients at sites including Peter MacCallum Cancer Centre (Melbourne, Australia).

Proxies

Public comparables and monitoring names used as representatives for the analysis.

Proxies

CytomX Therapeutics, Inc.

Halozyme Therapeutics, Inc.

Onconova Therapeutics, Inc.

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Clinical-stage oncology biotech with proenzyme-based Probody therapeutic platform; comparable pre-commercial stage and technology approach targeting solid tumors.

Halozyme Therapeutics, Inc.

NASDAQ:HALO

Biotech with enzyme-based oncology platform (PEGPH20) that transitioned from development to partnered commercial revenue; relevant downstream partnership model.

Onconova Therapeutics, Inc.

NASDAQ:ONTX

Clinical-stage biopharma focused on cancer therapies with similar micro-cap development-stage profile and single-asset pipeline risk.

Geographic

Region-level exposures that can distort the supply network.

Geographic

Australia (Headquarters)

Spain

Europe (Undisclosed location)

Peter MacCallum Cancer Centre

University of Jaén

University of Granada

European CDMO (Undisclosed)

Australia (Headquarters)

Corporate operations, R&D management, planned clinical trial site (Peter MacCallum Cancer Centre)

Peter MacCallum Cancer CentreExpected clinical trial site for Phase 1b FIH study of PRP

Spain

Academic R&D partnerships; drug discovery and preclinical research; potential clinical trial sites

University of JaénJoint research collaboration (cancer, anti-aging, PRP mechanism)

University of GranadaJoint research collaboration (cancer, anti-aging, PRP mechanism)

Europe (Undisclosed location)

CDMO manufacturing site for PRP GMP production (4,500sqm facility)

European CDMO (Undisclosed)GMP manufacturing partner for PRP Phase 1b supply

Concentration

Customer, supplier, or partner concentration exposures that can distort the supply network.

Other

Critical

Single-asset concentration risk: Company is entirely dependent on lead candidate PRP, which has not yet entered Phase 1 clinical trials. No diversified pipeline, no approved products, no commercial revenue.

Foundry

High

Manufacturing concentration: Company relies on a single undisclosed European CDMO for GMP production of PRP. No alternate manufacturing source identified. Raw material (bovine pancreas proenzymes) sourced from a single undisclosed supplier.

Other

Critical

Funding dependency: Company is dependent on financing from Hexstone Capital ($100M facility), GS Capital Partners, and periodic public offerings (e.g., $4M uplisting via D. Boral Capital). Negative cash flows from operations with no revenue.

Revenue mix

How the target's revenue mix translates into supply-chain leverage and dependency.

Product Revenue (PRP - Pre-commercial)

0.0%

$0.0B

Pre-revenue company with no approved commercial products. PRP is in preclinical-to-early clinical stage (Phase 1b FIH study planned for 2026). No downstream commercial customers or distribution partners exist.

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer